Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Return on Invested Capital (2016 - 2026)

Champions Oncology has reported Return on Invested Capital over the past 16 years, most recently at 0.6% for Q1 2026.

  • Quarterly results put Return on Invested Capital at 0.6% for Q1 2026, down 266.0% from a year ago — trailing twelve months through Jan 2026 was 0.6% (down 266.0% YoY), and the annual figure for FY2025 was 4.95%, up 1031.0%.
  • Return on Invested Capital for Q1 2026 was 0.6% at Champions Oncology, down from 0.57% in the prior quarter.
  • Over the last five years, Return on Invested Capital for CSBR hit a ceiling of 9.85% in Q1 2024 and a floor of 9.58% in Q4 2023.
  • Median Return on Invested Capital over the past 5 years was 0.05% (2022), compared with a mean of 0.18%.
  • Biggest five-year swings in Return on Invested Capital: tumbled -960bps in 2023 and later skyrocketed 1023bps in 2024.
  • Champions Oncology's Return on Invested Capital stood at 0.02% in 2022, then crashed by -49347bps to 9.58% in 2023, then skyrocketed by 56bps to 4.24% in 2024, then surged by 113bps to 0.57% in 2025, then tumbled by -206bps to 0.6% in 2026.
  • The last three reported values for Return on Invested Capital were 0.6% (Q1 2026), 0.57% (Q4 2025), and 0.76% (Q3 2025) per Business Quant data.